Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced hepatocellular carcinoma

Author:

Yang Zhenyun1,Wang Qianyu2,Hu Li1,Sima Xiaoxian3,Hu Dandan1,Zhou Zhongguo1,Chen Minshan1,Fu Yizhen1,Zhang Yaojun1

Affiliation:

1. Sun Yat-sen University Cancer Center

2. Peking University Cancer Hospital & Institute

3. Sun Yat- Sen University Cancer Center

Abstract

Abstract

Background Transarterial therapy (TAT), bevacizumab (Bev), and immune checkpoint inhibitors (ICIs) have individually exhibited efficacy in treating advanced-stage hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of the combination of these three treatments as a neoadjuvant modality in patients with locally advanced HCC. Methods The primary endpoint is overall survival (OS). The second endpoint is progression free survival (PFS), objective response rate (ORR), pathological response rate and safety. Results A total of 54 patients received standard systemic therapy comprising Bev combined with ICIs (Bev-ICIs group), 113 patients received direct surgery (Surgery group), and 273 patients received neoadjuvant therapy of TAT combined Bev plus ICIs, among which 79 patients (28.9%) underwent surgical resection after successful tumor downstaging (Neo-surgery group) while the remaining 194 patients (71.1%) received maintenance systemic therapies (Neo-maintenance group). Neoadjuvant following surgery demonstrated a prolonged OS in contrast to direct surgery (hazard ratio (HR) = 0.29, P = 0.0058). The median PFS time in the Neo-surgery and Surgery groups stood at 19.2 and 6.3 months, respectively (HR = 0.25, P < 0.0001). In patients failed to receiving resection after neoadjuvant therapy, the median OS was 22.8 months, whereas that for the standard care population was 19.7 month (HR = 0.53, P = 0.023). The median PFS time in Neo-maintenance group and Bev-ICIs groups was 11.2 and 6.4 months (HR = 0.60, P = 0.024). Conclusion The triple therapy regimen comprising TAT-Bev-ICIs emerged as a promising therapeutic strategy for locally advanced hepatocellular carcinoma (HCC) as a neoadjuvant intervention.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3